Grandma gives birth to her own grandchild

September 8, 2012

Cindy

Chicago, September 8: ?Setting foot in a hospital again, Emily and Mike Jordan couldn't help but feel anxious.

More than two years before, at age 29, Emily had been diagnosed with cervical cancer. But just before she was to undergo a radical hysterectomy, she was told that she was pregnant.

Faced with saving her own life or their unborn child's, the young couple made the excruciating decision to go forward with her surgery. It meant losing the baby, and forfeiting any chance at having their own children.

Or so they thought.

“I can't describe what that was like after finding out you have cancer, after finding out your chance of ever carrying a baby is gone,” Emily says, still stammering at times as she recounts that painful day in 2010.

Simply put, her body no longer had a place where a baby could grow.

But now, more than two years later, she and Mike had come from their suburban Chicago home to the labour and delivery department of a downtown hospital to realise the dream they thought was lost — to become parents, though not the way they, or most people, would have imagined.

Alongside them that day was Emily's mother, Cindy Reutzel — a fit, silver-haired 53-year-old grandmother whose profile revealed a round belly, a pregnant belly.

Reutzel was about to give birth to her own grandchild.

Just 34 years ago, Louise Brown, the first “test tube” baby, was born in Great Britain. The result? A veritable in-vitro baby boom.

It started with would-be mothers in their 20s and 30s. “Then people started pushing the envelope,” says Dr Helen Kim, director of the in vitro

fertilisation programme at the University of Chicago. “If you could help a menopausal woman in her 30s, could you help a menopausal woman in her 40s? And then it became, ‘Can you help a menopausal woman in her 50s?'

“And the answer is yes.”

Some older women were having their own babies. But more often, they were using egg donors to have their own children, or serving as surrogates or “gestational carriers”.

There was the 51-year-old grandmother in Brazil who gave birth to her twin grandchildren in 2007. There've been others, grandmothers in their 40s or 50s and even 60s.

Cindy Reutzel, Emily's mom, had a vague recollection of those stories. So when doctors shared the good news that they had been able to keep Emily's ovaries intact, Reutzel immediately made the offer.

“What if I carried your baby for you?” she asked.

Emily and Mike didn't take it too seriously at first. “We didn't really think that was a realistic option,” says Emily, who works in hospital administration.

It turned out, though, that it wasn't really that far-fetched after all, particularly for a young grandmother who's in good health, like Reutzel.

After a process that included psychological evaluation and hormonal manipulation to prepare their bodies, Kim eventually implanted Reutzel's uterus with an embryo created with an egg from Emily and Mike's sperm.

It was no easy process, with a regimen of hormonal shots. Work schedules were interrupted and vacations postponed. But Reutzel was committed.

“The thought of Emily and Mike not being able to have children and share that piece of their lives with someone just broke my heart,” says Reutzel, who lives in Chicago and is executive director at medical foundation. “I want Emily to have that connection with another human being like I had with her.”

As her belly grew, people started asking about “her baby”. But she was quick to tell them the story. This was not her baby, she was Grandma.

Admittedly, she says, she worried about the physical toll pregnancy might take, though her body handled it better than she expected. She also wondered how well she'd bounce back from a Caesarean section. That's how she had delivered Emily and her older brother, but that had been three decades ago.

Still, she reassured Emily and Mike throughout the pregnancy that the baby was fine, she was fine, everything would be fine.

Humour helped. Mike often teased his mother-in-law each time they'd take her to dinner or do something nice for her.

“Are we even yet?” he'd ask.

“Not yet,” she'd reply, laughing.

In truth, Mike and Emily knew there'd really be no way to repay this kind of gesture.

“This is a continuation of everything that she has done her entire life for me, which is to make sure that I have the best life possible,” Emily says.

All they could do, they said, was to promise to raise their baby as best they could. And that was enough for Reutzel.

“I know I gave a gift,” she says. “But I'm also getting so much in return.”

Last week, a few days after Emily's 32nd birthday, daughter sat next to mother, holding hands in the delivery room.

And Elle Cynthia Jordan was born.

“She looks just like you! She looks just like you!” Emily shouted, running from the delivery room to introduce their newborn to Mike.

Reutzel is recovering well. She even says she'd consider doing it again.

“When I watch both of them hold that baby and look into her face, it's like everything I could have imagined wanting for them — better than I could have imagined,” she says, her eyes filling with tears.

“This is what it was all about for me.”

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Y UDAYA CHANDAR
 - 
Monday, 13 Apr 2020

Dear Sir,

 

I am 77 but a very healthy person with remarkable immunity. I contracted Malaria fever in 1994 because of mosquito biting and I have not been sick anytime there after, not even for ordinary fever in the last 26 years.

 

I am sure you would like to conduct the trials on persons of varying criteria. I am sure you don't want to carry out the trials on perfectly healthy young individuals only. 

 

I am certain that  you want to try the vaccine on a 'common man' from 'general public.' I am ready for the trial and you can take me. I will be delighted. 

 

If you are not handling this matter kindly forward this mail to the correct agency.

 

I look forward to hearing from you.

 

Best regards.

 

If you are not moving forward, you are really moving backward.

Y Udaya Chandar

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 7,2020

Washington, Aug 7: US President Donald Trump on Thursday (local time) signed executive orders halting all transactions with Chinese applications TikTok and WeChat within 45 days, citing national security concerns, further escalating the tensions between Beijing and Washington.

"WeChat, a messaging, social media, and electronic payment application owned by the Chinese company Tencent Holdings Ltd., reportedly has over one billion users worldwide, including users in the United States. Like TikTok, WeChat automatically captures vast swaths of information from its users. 

This data collection threatens to allow the Chinese Communist Party (CCP) access to Americans' personal and proprietary information," Trump said in a statement.

Citing reasons for the ban on WeChat, the US President said that the application captures the personal and proprietary information of Chinese nationals visiting the US, thereby providing the CCP a mechanism to keep tabs on the Chinese citizens who may be "enjoying the benefits of a free society for the first time in their lives".

"In March 2019, a researcher reportedly discovered a Chinese database containing billions of WeChat messages sent from users in not only China but also the United States, Taiwan, South Korea and Australia. WeChat, like TikTok, also reportedly censors content that the CCP deems politically sensitive and may also be used for disinformation campaigns that benefit the CCP. 

These risks have led other countries, including Australia and India, to begin restricting or banning the use of WeChat. The US must take aggressive action against the owner of WeChat to protect our national security," he added.

Earlier, Trump had issued an order banning TikTok as it "reportedly censors content that the CCP deems politically sensitive, such as content concerning protests in Hong Kong and China's treatment of Uighurs and other Muslim minorities. 

TikTok may also be used for disinformation campaigns that benefit the CCP."
US politicians have repeatedly criticised TikTok, owned by Beijing-based startup ByteDance, of being a threat to national security because of its ties to China.

The development comes as China and the US are at loggerheads on a variety of issues including Hong Kong national security law, the South China Sea, the novel coronavirus and trade.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 30,2020

May 30: Warning of the tightrope walk ahead as governments battle the coronavirus crisis, Nobel laureate Peter Charles Doherty has expressed concern about densely populated countries such as India relaxing lockdown norms while also describing a complete shutdown as “an economic and social impossibility”.

The Australian immunologist, who cautioned that the number of COVID-19 cases will rise in the coming days, said the earliest time frame for an effective vaccine “going into large numbers of people” is nine to 12 months.

"If all goes well with testing, we could know if some of the candidate vaccines are both safe and effective as early as September/October. Then, rolling a vaccine out will depend on the type of product and how quickly it can be made, put in vials and so forth," Doherty told PTI in an email interview from Melbourne.

The novel coronavirus, he added, does not change fast like influenza and, from what is known so far, “the same vaccine should work everywhere”.

Doherty, who is with the Department of Microbiology and Immunology at the Doherty Institute, University of Melbourne, won the Nobel Prize for Medicine in 1996 for his discovery of how the body’s immune system distinguishes virus-infected cells from normal ones.

Discussing the lockdown, he said, "If it was purely a matter of hard science, everywhere should stay locked down. But that’s pretty much an economic and social impossibility.”

The expectation, he said, is the numbers will rise and limiting spread will depend on people acting responsibly and the capacity for rapid response and extensive contact testing.

“And in a densely populated country like India I think that it will be very difficult," the scientist said.

Several countries, including India, began relaxing lockdown norms in mid-May despite the WHO’s warning about a second wave. India’s lockdown began on March 25 and has since been extended. The fourth phase ends on Sunday.

Asked whether there are any alternatives to a lockdown, the 79-year-old said, "There is no other option other than closing borders. South Korea, for example, conducted massive, intensive testing and contact tracing in a wealthy country with a very disciplined population. Otherwise, not till we have effective vaccines."

He added that he personally doesn’t see the point of closing borders for people coming in if there’s already a high incidence of disease in the community, “unless it’s to avoid the need to care for them and use scarce hospital beds".

According to Doherty, the coronavirus "is a new virus which has come straight out of nature".

“It (the virus) has moved so rapidly across the world because of people travelling on international planes as well as tourist ships," he added.

The immunologist also warned against the use of hydroxychloroquine to treat COVID-19, and said current and planned trials of the anti-malaria drug should be stopped.

“My understanding is that the use of the drug in severe disease is definitely contra-indicated, but it’s not yet clear whether, if taken under medical supervision, it could have some useful effect if taken early on, or as a preventive. Those trials just haven’t been done properly," Doherty noted.

The Indian Council of Medical Research (ICMR) has backed the use of hydroxychloroquine as a preventive against COVID-19 even after the WHO suspended clinical trials of the drug citing safety concerns.

Asked whether plasma therapy can be an effective treatment for COVID-19, Doherty said, "We lack good properly controlled trials but, especially if the plasma has been tested for antibody levels and there’s evidence of good activity, it could be helpful. If I had the disease and was offered plasma therapy I would certainly accept, but I would not take hydroxychloroquine."

Doherty is also very optimistic about herd immunity developing against the SARS-CoV-2 infection.

"We think that (herd immunity) will cut in and have an obvious effect when, say, 60 per cent of people have been infected. Best hope is to boost herd immunity with a vaccine," he stated.

Herd immunity is a form of indirect protection from infectious disease that occurs when a large percentage of a population has become immune to an infection, whether through vaccination or previous infections.

The number of COVID-19 cases have crossed 5.9 million and the fatalities 3,65,000, according to the Johns Hopkins University on Saturday. 

In India, the death toll has risen to 4,971 and the number of cases to 1,73,763, according to the Union Health Ministry on Saturday.

Several states, including Bihar, Uttar Pradesh, Madhya Pradesh, Jharkhand and Chhattisgarh, have reported a rise in number since lockdown norms were relaxed in early May and migrant workers reached home.

In Uttar Pradesh, for instance, the number of infections rose from around 3,000 on May 4 to 6,532 on May 26. Similarly, Bihar’s numbers increased from around 500 to over 2,700 in the period.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.